Photo: Alex & Martin

Uppsala BIO helps Testa Center off to a flying start 

In parallel with the construction of Testa Center, another, perhaps not as apparent but equally important activity has been going on: developing the infrastructure and processes needed for the project flow through the centre to run smoothly and to ensure that it is well utilised. Part of this work has been to establish Testa Center as an integral component of the Swedish innovation support system, a mission that suited us at Uppsala BIO very well given our strong national networks. Even before the opening ceremony, we can note that all four labs in Testa Center are more or less fully occupied throughout the autumn!

Testa Center invigning
Lotta Ljungqvist, CEO GE Nordics and CEO Testa Center, demonstrates equipment in Testa Center for Mikael Damberg, Minister for enterprise and innovation, and Emmanuel Ligner, CEO GE Healthcare Life Sciences.
Photo: Alex & Martin

Process based on successful BIO-X methodology

Uppsala BIO has developed a process for announcing, selecting and implementing early proof-of-concept projects in life science – BIO-X – which ran successfully for over ten years. This experience, together with the fact that we at Uppsala BIO have strong links with many of Sweden’s innovation environments, prompted us to get involved in developing similar processes and infrastructure together with Testa Center. A mission we gladly took on, as a centre like this has incredible potential for both regional and national growth in life science.
During the winter, we have drawn up a process for project application and selection, much of it based on BIO-X methodology. The first step is a feasibility assessment: can the project be carried out in Testa Center, is suitable equipment etc. available, or is there another lab at, for example, a university or commercial partner, that is more appropriate? After passing this assessment, a brief application / project description is developed.

Key role for Advisory Board

The application process itself is managed by Uppsala BIO in close contact with Testa Center staff and there is a good reason for this. Since Testa Center is a wholly-owned subsidiary of GE Healthcare Life Sciences, the US-based company wants to maintain a neutral stance to the projects: it does not want to be responsible for selection, prioritisation or possible funding. This is instead handled by a separate, hand-picked Advisory Board consisting of senior experts with skills from academia and industry. This measure ensures a commercial neutrality towards the projects. The board also advises on which projects will receive access to Swelife’s verification funding, which is available to Testa Center projects during a start-up period.
Testa Center thus opens its doors for projects already in August 2018, but since late autumn 2017, we have met project teams that are interested in using the centre. In this work, and in collaboration with my colleague Helena Ströberg, I have been in touch with teams from all over the country, helping them with their application process and the packaging of their project proposals. This coaching work has been incredibly fun and educational. It also shows the breadth of projects attracted to Testa Center: both mammalian and bacterial expression systems, the production of biopharmaceuticals and other biological products, as well as more technically-oriented projects that have the potential to streamline bioproduction in general.

Verification funding from Swelife a valuable incentive

Accepted projects have come from small start-ups and academic groups, but large companies are also represented. Many are linked to one of Sweden’s business incubators or innovation offices, and we therefore try to involve their regional coaches in the work as much as possible. The verification funding from Swelife has proven to be a very valuable tool in this work. We feel that it lowers the threshold and risk for projects in taking the important step of developing their production processes.
We will continue to be active throughout the country in order to spread the word about the opportunities that Testa Center offers, and to come into contact with projects that could benefit from the facility. In August / September, we will be putting in appearances in Stockholm, Gothenburg, Malmö and Copenhagen, for example. 
Finally, we welcome all upcoming project teams to Uppsala. Together with the Testa Center staff, we look forward to meeting you all and supporting your exciting projects in their expansion phase!
Do you want ongoing information and updates about Testa Center activities? Simply sign up for our newsletter at

Testa Center in brief: 

  • Access to a unique equipment park – four parallel industrial production labs (non-GMP) up to pilot scale based on single-use technology
  • Access to bioprocessing expertise – dedicated GE staff available for advanced support if desired
  • Cost-effective – develop, test, verify and set production parameters before investing in own equipment or outsourcing production to another party
  • Full control over your IP and your data – GE makes no claims to rights
  • Facility for advanced courses / training in the production of biological products – open to all Swedish universities
  • Authentic test environment for new process and digitization technologies
  • Part of the Swedish innovation support system – simple access to commercialisation support

Kristin Hellman
M.Sc., Business Development
Uppsala BIO


Kristin Hellman. M.Sc., Business Development. “I focus on facilitating interaction between large companies and small start-ups and academic projects in order to accelerate the development of promising new products and technologies.”

Contact me
- 2019-06-25

Scaling Up the Value: BioLamina

Uppsala BIO has an important role to connect and contribute to the overall growth of Life Sciences, nationally and internationally, both for academic institutions and companies.
Since the beginning of Testa Center, Uppsala BIOs team has as an external project coordinator role and has developed the application and selection process based on the BIO-X methodology.


Helena Ströberg, Uppsala BIO - 2019-06-19

Breaking down the numbers 2017-2018

The overall goal of Uppsala BIO is to contribute to Upsala's vision of 70,000 new jobs in 2050. Of these, at least 3500 jobs will be created in the life science sector.


Kristin Hellman, Uppsala BIO - 2018-08-22

Uppsala BIO helps Testa Center off to a flying start

Process based on successful BIO-X methodology.


Kristian Sandberg, Director of DDD, SciLifeLab in Uppsala - 2018-08-21

How to bridge the ‘Valley of Death’

The SciLifeLab Drug Discovery Model.


Erik Forsberg, Uppsala BIO - 2018-06-15

“You can make a holding company profitable, but it takes a bit of luck.”

This autumn, Lars Jonsson, CEO of UU Holding since 1998, retires and hands over a very successful investment business to his successor. “UU Holding is nothing short of a success story,” writes Uppsala BIO’s Erik Forsberg. Lars Jonsson has proven that it is possible to make a holding company profitable.


Magnus Engevik, Uppsala BIO - 2018-05-21

Uppsala’s innovation support system works! Award-winning Kontigo Care is the latest proof.

“With its high costs and huge suffering for those affected as well as their relatives, alcohol abuse is one of our major social problems. Kontigo Care’s work on digital biomarkers is one of the most exciting things I’ve witnessed during my career,” writes Uppsala BIO Buiness Developer Magnus Engevik.


Margaretha Gadnell, Uppsala BIO - 2018-04-25

Spotlight Uppsala’s unique resource!

Uppsala’s life science industry is healthy and developing well. More than 100 life science companies can be found here and in 2016 they employed about 5000 people and had a combined turnover of approximately SEK 27 billion.


Christina Wass, Project leader, Innovation Akademiska - 2017-12-13

“What happens in Vegas stays in Vegas…”

During 52 hours, staff from the Academic Hospital, AbbVie, Bristol Myers-Squibb and Microsoft worked together to develop and test new ideas and models for early diagnosis and better treatment of cancer. Now the experiences of Sweden's first “Innovation Race” can be summed up.


Lovisa Case - 2017-11-07

50 years of excellence – it all started with a collaboration between academia and industry!

2017 marks the 50 year anniversary of the RAST-method. Learn about the history and see how Uppsala BIO and UU Innovation are addressing future challenges in asthma and allergy diagnostics.


Johan Gómez de la Torre - 2017-10-25

Sweden needs new regulations and ways for collaboration to stay ahead in healthcare and the life sciences

Challenges and opportunities for countries wanting to take a leading role in life sciences, with focus on the future role of Sweden, was the topic of a seminar in May 2017. In our blog Johan Gómez de la Torre, Business Development Manager, Stockholm Science City digest the report.


Anna Ridderstad Wollberg - 2017-10-16

Call for proposals: A pull to transform inventions into innovations

How do we pull out the good ideas that may become new innovative products or treatments for the benefit of patients? Calls for project proposals may be the pull that is needed.


Madeleine Neil, Uppsala Health Summit - 2017-10-08

Uppsala Health Summit 2017: Time for the world to meet on Infectious Disease Threats  

10 – 11 October Uppsala Health Summit gathered 200 decision makers and experts from 30 different countries in a discussion about global threats from zoonotic infectious diseases. 


Karin Meyer, CEO, Swedish Pharmaceutical Society - 2017-10-02

EMA needs Sweden’s strong scientific environment

Karin Meyer, CEO, Swedish Pharmaceutical Society about what Sweden can offer the EMA and EU.


Margaretha Gadnell, Uppsala BIO - 2017-09-26

Check out EIT Health and its Uppsala activities

The purpose of EIT Health is to accelerate entrepreneurship and innovation for healthy living and active ageing in Europe.


Margareta Gadnell, Uppsala BIO - 2017-09-18

Fast-growing companies in Uppsala’s life science cluster

Between 2014 and 2015, the number of employees in this category increased by 11%. If we include 2013 as well, the increase is almost 20%.


Erik Forsberg, Uppsala BIO - 2017-08-28

Financial support and further action!

Our long-term goal is, as always, to contribute to growth by driving actions that complement those of the private and public sectors.


Annakarin Svenningsson, Uppsala BIO - 2017-08-15

Tough competition prior to relocation of EMA after Brexit

Among the arguments stressed in the Swedish application to convince other member states that Sweden and Stockholm is best suited to host the EMA, is the Swedish Medical Products Agency (MPA) in Uppsala.


- 2020-12-02


A visionary who wants to make a difference

Life Science is entering a new and exciting time, sometimes called the fourth industrial revolution. To meet these opportunities, the STUNS foundation has recruited Björn Arvidsson to fulfill the role of the new Managing director of the foundation's life science branch Uppsala BIO. Björn’s most recent engagement has been at the Swiss pharmaceutical and diagnostics giant Roche.